Aditxt (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing and deploying promising health innovations, has announced a new president for its majority-owned subsidiary, Pearsanta Inc. According to the announcement, Christoper Mitton has been named president of the subsidiary, which focuses on precision health. Mitton has an impressive career of leadership in the medical diagnostics space spanning more than two decades. His experience includes building and leading successful commercial operations, as well as gaining impressive expertise in product commercialization, business development, and strategic sales and marketing.
According to the announcement, Mitton will continue to serve as CEO of MDNA Life Sciences Inc. His previous experience has included heading sales operations at Cancer Genetics Inc., leading the North American commercial expansion for Ipsogen and managing the entire personalized healthcare portfolio for Qiagen.
“We are thrilled to welcome Chris to Pearsanta at this pivotal moment,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “Our mission at Aditxt is to build and accelerate companies focusing on innovative health solutions that tackle some of the most critical challenges in healthcare. We believe that Chris’s leadership will be key as we seek to drive the commercial success of Pearsanta, advancing breakthrough innovations and creating value for all stakeholders. We feel strongly that his personalized healthcare and commercial strategy expertise make him the ideal leader to guide Pearsanta’s next growth phase as we accelerate our precision health initiatives.”
To view the full press release, visit https://ibn.fm/eedw8
About Aditxt Inc.
Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt’s ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to “Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, including Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies. Adivir(TM) Inc. focuses on enhancing national and population health and impacting public health globally. Pearsanta(TM) Inc. delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit www.Aditxt.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN